博彩公司排名

个人简介

文卓谦博士，博彩公司排名-博彩公司评级 副教授，博士生导师，中山大学引进人才，“逸仙学者计划”新锐学者。

2013年博士毕业于香港大学医学院，导师为梁如鸿教授；2015-2019在哈佛大学麻省总医院开展博士后研究工作，合作导师为David Scadden；2019-2024于香港大学就任研究助理教授。2024年任职于博彩公司排名 。

主要研究急性髓系白血病（Acute Myeloid Leukemia）的发生与复发的分子调控机制（包括表观遗传、代谢与免疫的相互作用）并研发对应的治疗方案，以改善白血病的治疗结果。相关研究成果以第一作者或者通讯作者发表在Blood，Leukemia等高水平杂志。

学术成果

代表性论著 (*co-first author; #corresponding author)

1. Zeng X, Wang YP, Man CH#. Metabolism in Hematopoiesis and Its malignancy. Adv Exp Med Biol. 2023:1442:45-64
2. Man CH*#, Lam W*, Dang CC*, Zeng X, Zheng L, Chan NM, Ng KL, Chan KC, Kwok TH, Ng TC, Leung WY, Huen SY, Wong CL, So CC, Dou Z, Goyama S, Bray MR, Mak TW, Leung AY. Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML. Blood. 2023 Dec 7;142(23):2002-2015
3. Man CH*#, Zeng X*, Lam W*, Ng TC, Kwok TH, Dang KC, Leung TW, Ng NK, Lam SS, Cher CC, Leung AY. Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication. Leukemia. 2022 Aug;36(8):1990-2001. doi: 10.1038/s41375-022-01606-0
4. Man CH*, Mercier FE, Liu N, Dong W, Stephanopoulos G, Jiang L, Jung Y, Lin CP, Leung AY, Scadden DT. Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive hematopoietic progenitor growth. Blood. 2022 Jan 27;139(4):502-522. doi: 10.1182/blood.2021011563
5. Man CH*, Wan HX*, Fung TK*, Chow HC, Fan AC, Wan TS, Tanaka T, So CW, Kwong YL, Leung AY. Suppression of SOX7 by DNA methylation and its tumor suppressive role in acute myeloid leukemia. Blood. 2015;125:3928-36. doi:10.1182/blood-2014-06-580993
6. Gill H*, Man CH*, Ip AH, Choi WW, Chow HC, Kwong YL, Leung AY. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-Like Tyrosine Kinase-3 internal tandem duplication positive acute myeloid leukemia. Haematologica. 2015;100:e250-3. doi: 10.3324/haematol.2014.123034.
7. Man CH*, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD AML. Blood. 2014;123:2530-9. doi: 10.1182/blood-2013-07-512194
8. Man CH*, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness. Blood. 2012;119:5133-43. doi: 10.1182/blood-2011-06-363960